Zepbound Legal and Patent Challenges

FDA Approval Timeline and Regulatory Basis

The FDA approved Zepbound (tirzepatide) on November 8, 2023 under a priority review designation for chronic weight management in adults with obesity or overweight plus at least one weight-related condition [1]. The approval rested primarily on the SURMOUNT clinical trial program, a series of four phase 3 randomized controlled trials enrolling over 5,000 participants across global sites.

SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced a mean body weight reduction of 22.5% from baseline at 72 weeks, compared with 2.4% for placebo [2]. That result represented one of the largest weight-loss magnitudes ever recorded for a pharmacotherapy in a randomized trial. The 10 mg dose achieved 21.4% and the 5 mg dose achieved 16.0%, each significantly exceeding placebo (P<0.001 for all comparisons) [2].

Tirzepatide had already received FDA approval under the brand name Mounjaro in May 2022 for type 2 diabetes [3]. The weight management indication under the Zepbound brand created a separate regulatory pathway, with distinct labeling, dosing guidance, and promotional materials. This dual-brand strategy gave Eli Lilly separate commercial positioning but also introduced complexity around off-label prescribing, insurance coverage disputes, and patent scope questions that now feed into active litigation.

Patent Portfolio and Exclusivity Window

Eli Lilly holds a dense patent portfolio around tirzepatide. The protection spans the compound itself, its manufacturing process, specific formulations, auto-injector device designs, and methods of treatment for both diabetes and obesity indications.

Core composition-of-matter patents on the tirzepatide molecule extend into the early-to-mid 2030s based on filings listed in the FDA Orange Book [4]. The Endocrine Society has noted that GLP-1 receptor agonist patent estates tend to be broader and more layered than those of older diabetes drug classes, creating what the Society described as "a complex intellectual property environment that may delay biosimilar or generic entry" [5]. Eli Lilly has filed continuation patents and additional method-of-use claims that could extend exclusivity even further.

No abbreviated new drug application (ANDA) or biosimilar application (under the 351(k) pathway) for tirzepatide has been accepted by the FDA as of May 2026 [4]. The peptide's classification as a synthetic peptide rather than a biologic means it falls under the traditional NDA pathway, which affects the regulatory route any generic competitor would need to follow. This distinction matters. It means the Hatch-Waxman framework governs patent challenges, not the Biologics Price Competition and Innovation Act (BPCIA) that applies to monoclonal antibodies and other large biologics.

Compounding Pharmacy Litigation

The most visible legal conflict surrounds compounding pharmacies. Starting in late 2023, when demand for tirzepatide surged and supply constraints persisted, 503A and 503B compounding pharmacies began producing and selling compounded tirzepatide, citing the drug's listing on the FDA Drug Shortage Database [6].

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound copies of commercially available drugs when those drugs appear on the FDA shortage list. Section 503B permits outsourcing facilities registered with the FDA to do the same at larger scale without individual patient prescriptions. Compounding pharmacies used this statutory opening to offer tirzepatide at prices often 70% to 85% below the list price of branded Zepbound [7].

Eli Lilly responded aggressively. The company filed lawsuits in federal courts in 2024 against multiple compounding pharmacies and wellness clinics, alleging trademark infringement, false advertising, and violations of the Federal Food, Drug, and Cosmetic Act [7]. Lilly's central legal argument was that many compounded products were not true copies of tirzepatide but rather contained tirzepatide salt forms (such as tirzepatide sodium) that the FDA had not approved and that differed structurally from the branded product.

The FDA supported Lilly's position in part. In October 2024, the agency issued a statement clarifying that compounded products using modified salt forms of tirzepatide were not the same as the FDA-approved drug and therefore could not rely on the shortage exemption [6]. The FDA simultaneously removed tirzepatide from the drug shortage list, eliminating the statutory basis for 503A and 503B compounding [6].

Several compounding pharmacies challenged this decision. The Outsourcing Facilities Association filed suit against the FDA in the U.S. District Court for the Western District of Texas, arguing that the agency's shortage resolution was premature given ongoing access barriers and that the salt-form distinction lacked scientific merit [7]. As of early 2026, this litigation remains active, with preliminary injunctions having been granted and reversed at different stages.

FDA Shortage Status and Access Implications

The FDA drug shortage listing for tirzepatide became a focal point of regulatory and legal conflict. Tirzepatide first appeared on the shortage list in late 2022, shortly after the Mounjaro approval triggered demand that exceeded Lilly's manufacturing capacity [6].

During the shortage period, compounding pharmacies filled a gap. Patients unable to obtain branded Mounjaro or Zepbound turned to compounded alternatives, often at a fraction of the cost. A 2024 analysis published in JAMA Internal Medicine estimated that approximately 1.5 million Americans used compounded GLP-1 receptor agonists during the peak shortage months, with tirzepatide and semaglutide representing the majority of compounded volume [8].

The FDA's decision to resolve the shortage in October 2024 was based on Eli Lilly's demonstration that it could meet projected demand through expanded manufacturing at its facilities in Research Triangle Park, North Carolina, and Alzey, Germany [6]. The agency gave compounding pharmacies a wind-down period to exhaust existing stock. But the transition was not smooth. Patient advocacy groups argued that the branded product's list price (approximately $1,060 per month without insurance) remained a barrier to access even when supply was adequate [9].

The American Association of Clinical Endocrinology (AACE) issued guidance in 2024 acknowledging the tension: "Access to effective anti-obesity medications must be balanced against safety standards that ensure product quality and dosing accuracy. Compounded peptides lack the batch-to-batch consistency and sterility assurance of FDA-approved products" [10].

Zepbound Label: Warnings and Restrictions

The Zepbound prescribing information carries specific warnings that shape both clinical use and legal exposure [3]. The boxed warning addresses thyroid C-cell tumors. In rodent studies, tirzepatide caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether tirzepatide causes MTC in humans remains unknown. The label contraindicates Zepbound in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [3].

The warnings and precautions section also covers acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin secretagogues, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications (relevant for Mounjaro but cross-referenced), and suicidal behavior and ideation [3]. The FDA required Eli Lilly to add the suicidal ideation warning following a review of post-market adverse event reports across the GLP-1 receptor agonist class, though the agency noted that "a causal relationship has not been established" [11].

From a liability standpoint, these label warnings serve as both shield and sword. They protect Eli Lilly from failure-to-warn claims when adverse events matching the labeled risks occur. But they also create a legal framework under which plaintiffs can argue that the warnings were inadequate or that Lilly failed to update them promptly as new safety signals emerged. Several personal injury lawsuits filed in 2024 and 2025 allege that Lilly underrepresented the severity and frequency of gastroparesis and intestinal obstruction events associated with tirzepatide and other GLP-1 receptor agonists [12].

Post-Market Safety Surveillance

The FDA's post-market requirements for Zepbound include long-term observational studies and mandatory adverse-event reporting through the FDA Sentinel System and the FDA Adverse Event Reporting System (FAERS) [11].

SURMOUNT-4 (N=670) provided 88-week data showing that participants who continued tirzepatide 15 mg maintained a 21.4% weight loss from baseline, while those switched to placebo regained weight, ending at 9.9% loss from the pre-randomization baseline [13]. This trial informed the label's guidance on treatment duration but also raised questions about weight regain that feed into ongoing litigation about informed consent and marketing representations.

A post-marketing surveillance study published in The Lancet in 2025 analyzed FAERS data from the first 18 months following Zepbound's approval and found adverse event reporting rates for pancreatitis (0.12%), gallbladder events (0.23%), and gastroparesis (0.08%) consistent with the rates observed in clinical trials [14]. The European Medicines Agency (EMA) has also maintained active monitoring through its EPAR review process and Periodic Safety Update Reports (PSURs) for tirzepatide, which is marketed as Mounjaro across EU member states for type 2 diabetes but has not yet received a separate weight management indication in Europe as of May 2026 [15].

The Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity recommended tirzepatide as a first-line pharmacotherapy option, while noting that "long-term cardiovascular outcomes data for tirzepatide in patients treated primarily for obesity are still being collected in the ongoing SURPASS-CVOT and SURMOUNT-MMO trials" [5].

Legislative and Policy Dimensions

Beyond courtroom litigation, Zepbound faces legislative headwinds. The Medicare program does not cover anti-obesity medications under Part D, a statutory exclusion that affects approximately 65 million beneficiaries [9]. The Treat and Reduce Obesity Act, reintroduced in Congress in 2024, would lift this exclusion, but it has not passed as of May 2026.

Several state attorneys general have opened investigations into the pricing practices of GLP-1 receptor agonist manufacturers, including Eli Lilly [9]. These investigations focus on whether list prices bear a reasonable relationship to manufacturing costs and whether patient assistance programs function as advertised. Eli Lilly's LillyDirect platform, launched in 2024 to sell Zepbound directly to consumers at lower prices (as low as $399 per month for self-pay patients), may mitigate some of this scrutiny but introduces its own regulatory questions about pharmacy law and direct-to-consumer drug distribution [7].

The Federal Trade Commission (FTC) has also signaled interest in GLP-1 marketing practices, issuing warning letters in 2025 to telehealth platforms making unsupported efficacy claims about compounded tirzepatide products [11]. These enforcement actions intersect with Eli Lilly's private litigation against compounders, creating a multi-front regulatory environment that will shape tirzepatide's commercial trajectory for years.

Patients prescribed Zepbound should verify their supply comes from an FDA-approved source, confirm insurance coverage or self-pay pricing through LillyDirect or authorized pharmacies, and report any adverse events directly to the FDA MedWatch program or their prescribing clinician.